Ph1 T-Regulatory Cells in Amyotrophic Lateral Sclerosis
| 対象疾患 | ALS |
|---|---|
| 相 | 第1相 |
| スポンサー | The Methodist Hospital Research Institute |
| ステータス | 完了 |
| 参加者数 | 3 名 |
| 介入（薬剤） | Autologous T-regulatory lymphocytes, Interleukin-2 |
| 開始日 | 2016年5月16日 |
| 完了日 | 2018年1月5日 |
| 結果公開日 | 2026年6月17日 |
概要
Open-label pilot study to determine the safety and tolerability of autologous CD4+ CD25+ regulatory T cells infusions with concomitant subcutaneous IL-2 injections taken 3 times per week in 3 participants with ALS.
Number of Participants With Treatment-related Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE v4.0) & Medical Dictionary for Regulatory Activities (MedDRA).
| Treatment Arm | 0 Participants |
|---|
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Ed — Shionogi
- Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic L — Shionogi
- Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) — Shionogi
- Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) — Shionogi
- Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis — Shionogi
- Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS — Shionogi